ITEL
23.2.2024 18:36:34 CET | Business Wire | Press release
itel, the global leading smart life brand committed to providing affordable and good quality consumer electronic products, is poised to redefine its visual identity with the spectacular launch of its new logo at the iconic Great Pyramids of Giza in Egypt on February 22. This momentous occasion will not only mark a significant evolution in itel’s brand image but also serve as a platform to engage and celebrate with esteemed partners and customers worldwide, especially customers from the Middle East and North Africa region.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240222762808/en/
itel successfully launched its 2024 brand launch event at Egyptian Pyramids (Photo: Business Wire)
The unveiling ceremony at the Egyptian Pyramids signifies itel’s commitment not only to technological innovation but also to creating a memorable and immersive experience for attendees. The event will kick off with a breathtaking display of opening fireworks, setting the stage for an evening of celebration and anticipation, followed by an inspiring opening speech. Subsequently, attendees will be treated to a captivating logo Show, where the new logo design will be unveiled with a profound interpretation of its significance to itel’s brand identity.
As part of the event, itel will officially launch the highly anticipated itel P55 series smartphones, including P55+, P55, and P55 5G. These smartphones boast three major technological upgrades: 45W PowerCharge technology with three-gear smart charging; iBoost game space, optimizing the gaming experience. And itel’s first 5G smartphone P55 5G, providing a fast browsing experience for entry-level 5G network customers in emerging markets.
In addition to the smartphone launch, itel also introduced a range of smart life accessories, including smartwatch E1, with features such as blood oxygen monitoring, heartbeat tracking, and health management, intelligent earbuds BudsAce, featuring noise reduction and superior sound quality, and other reliable and affordable home appliances and innovative kids electronics, as part of its commitment to a holistic smart lifestyle.
“We are thrilled to welcome esteemed partners, prominent media representatives, and KOLs to our grand unveiling at the Egyptian Pyramids,” said Steven Yang, North Africa Regional Director of itel. “This event is not merely a product launch. It's an opportunity for friendly exchanges, fostering close customer relationships, promoting future collaborations, and maintaining long-term, close contact with our valued partners. We aim to demonstrate the unparalleled service level of itel’s international brand and showcase our commitment to creating lasting connections in this vibrant and dynamic region.”
The gathering at the Egyptian Pyramids, one of the Eight Wonders of the World, symbolizes itel's transition into a daring new era characterized by innovation and enduring style. Be prepared to witness the unfolding of a new chapter in the brand’s legacy, marking its unwavering commitment to delivering not just technology but a refined and immersive experience.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240222762808/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Announces Clinical Milestone with First Patient Dosed in Phase 1 Trial of IDEAYA’s First-in-Class B7H3/PTK7 Bispecific TOP1 ADC IDE03428.2.2026 01:00:00 CET | Press release
IDE034 is a B7H3/PTK7 bispecific TOP1 ADC designed to target tumor cells expressing both B7H3 and PTK7 preferentially, and is being evaluated as monotherapy and in combination with IDEAYA’s PARG inhibitor IDE161. IDEAYA has dosed the first patient in its Phase 1 trial of IDE034, initially evaluating safety, tolerability, and PK. First dosing triggers a $5 million milestone payment to Biocytogen under the companies’ option and license agreement. Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that its partner IDEAYA Biosciences, Inc. (“IDEAYA”; Nasdaq: IDYA) has dosed the first patient in IDEAYA’s Phase 1 dose-escalation/expansion clinical trial of IDE034, an investigational B7H3/PTK7 bispecific TOP1 ADC. Pursuant to the companies’ option and license agreement, first patient dosing triggers a $5 million
IQM and Real Asset Acquisition Corp. to Host Conference Call/Webcast to Discuss Proposed Transaction27.2.2026 13:00:00 CET | Press release
IQM Finland Oy, a global leader in full-stack superconducting quantum computers (“IQM”, “IQM Quantum Computers” or the “Company”), and Real Asset Acquisition Corp. (Nasdaq: RAAQ), a special purpose acquisition company (“RAAQ”), announced that they will host a conference call to discuss their recently announced business combination, including certain transaction highlights. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260227472716/en/ IQM Radiance quantum computer As previously disclosed, on February 23, 2026, IQM and RAAQ announced they have entered into a definitive business combination agreement, which will result in IQM becoming a public company and listing American Depositary Shares on one of the two leading U.S. stock exchanges. The transaction provides funding with the aim to accelerate IQM’s technology and commercial development towards fault-tolerance quantum computing, further advancing its position as a leading p
HighRadius Launches $0 Implementation Fee, $0 Subscription Fee via Outcome Based Pricing for oCFO Software27.2.2026 12:00:00 CET | Press release
HighRadius launches Office of the CFO first Outcome Based Pricing with $0 Implementation fee and $0 Subscription until Go-Live. Customers only pay a fraction of realized gains based on P&L impact. Chapter 1: Outcome Based Pricing (OBP)Introduction of OBP: HighRadius, a provider of 190+ AI agents for Order-to-Cash, Accounts Payable, Record-to-Report, and Treasury introduces Outcome Based Pricing (OBP). Three Components of OBP: Customers pay a) $0 in Implementation fees, b) $0 in Subscription fees until Go Live, c) HighRadius earns a fraction of the actual savings realized by the client. Chapter 2: US GAAP & ASC 606 ConstraintsNot Designed for Innovation: The traditional ASC 606 model requires companies to standardize and recognize revenue based on contractual obligations. For a traditional SaaS subscription, the obligation is access to software over time. AI agents are designed to deliver quantifiable, real-time Business Outcomes that do not fit the traditional accounting framework. Cha
Kioxia Appoints Yoshihiko Kawamura as Chief Financial Officer27.2.2026 09:15:00 CET | Press release
Kioxia Holdings Corporation (TOKYO:285A), a world leader in memory solutions, today announced the appointment of Yoshihiko Kawamura as Chief Financial Officer (CFO), effective April 1, 2026. Mr. Kawamura brings extensive international experience to Kioxia, having held assignments at Mitsubishi Corporation’s U.S. headquarters, served as General Manager of its Chicago office, and completed a tenure at the World Bank. At Hitachi, Ltd., he held senior leadership positions, including Chief Strategy Officer (CSO), Chief Financial Officer (CFO), and Chief Risk Management Officer (CRMO), where he was instrumental in leading the company’s management reforms. Since joining Kioxia as Executive Vice President in June 2025, Mr. Kawamura has worked closely with the executive team to advance the business through strategic capital and financial planning. Following its initial public offering on the Prime Market of the Tokyo Stock Exchange in December 2024, Kioxia is entering a new phase of growth char
DNP Invests in Rapidus to Support the Establishment of Mass Production for Next-Generation Semiconductors27.2.2026 08:18:00 CET | Press release
Will accelerate the development and mass production of EUV lithography photomasks Dai Nippon Printing Co., Ltd. (DNP, TOKYO:7912) today announced that it has participated in Rapidus Corporation’s funding round as one of the round investors. This strategic funding initiative supports Rapidus’ plan to steadily progress from its current R&D phase to mass production of 2nm (10⁻⁹ meters) logic semiconductors by 2027. Through this initiative, DNP will advance the development and mass production of EUV lithography photomasks and support Rapidus as it establishes a mass production system for 2nm & next-generation semiconductors. Background In recent years, the rise in energy consumption, in line with increased data generation, has become a challenge, driving demand for next-generation semiconductors capable of improving device performance and reducing power consumption. Next-generation semiconductors manufactured using EUV lithography enable the formation of finer patterns on silicon wafers co
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom